Adlai Nortye Ltd. American Depositary Shares (ANL) Insider Trading Activity

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Show less

Over the last 12 months, insiders at Adlai Nortye Ltd. American Depositary Shares have bought $0 and sold $0 worth of Adlai Nortye Ltd. American Depositary Shares stock.

On average, over the past 5 years, insiders at Adlai Nortye Ltd. American Depositary Shares have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,700 shares for transaction amount of $168,717 was made by RHODES THOMAS L (director) on 2004‑09‑27.